A comparative study of efficacy of atorvastatin, rosuvastatin, and atorvastatin + fibrates as lipid lowering agents

Karunasree Nagarur, Yamini Vadlamannati, Narasimha Rao Raja


Background: Hypercholesterolemia patients are at high risk of coronary heart disease. National cholesterol education programme (NCEP) Adult Treatment Panel III guidelines provide the option of aggressively lowering Low-density cholesterol in them. Presently the standard therapy of hypercholesterolemia is by HMG co-A reductase inhibitors. Present study shows that Rosuvastatin is better than Atorvastatin, Atorvastatin and Fibrate is better than Atorvastatin monotherapy in management of hypercholesterolemia.

Methods: The present research was an observational study conducted at Government general hospital, Nizamabad. A total of 150 patients on treatment for hypercholesterolemia for more than one year were enrolled in our study. They were divided into three groups. Group I: Atorvastatin (20 mg) (n=96; 64%); Group II: Rosuvastatin 10 mg (n= 41; 27.33%); Group III: Atorvastatin (20 mg) + Fibrate (145 mg) (n=13; 8.66%).

Results: Rosuvastatin is better than Atorvastatin and Atorvastatin with fibrates reduces LDL, TG more than Atorvastatin alone.

Conclusions: Rosuvastatin is better than Atorvastatin and Combination of atorvastatin with fibrates reduces LDL-Cholesterol and triglycerides more than atorvastatin alone.


Atorvastatin, Rosuvastatin, Atorvastatin + Fibrates, LDL (low density cholesterol), TG (triglycerides), HDL (high density cholesterol), TC (total cholesterol)

Full Text:



Hunninghake DB, Ballantyne CM, Maccubbin DL. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clinical therapeutics 2003;25:1670-86.

Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109(23):2-7.

Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall. Mar2006. Nat Clin Pract Cardiovasc Med. 2006;3(3):144-53.

Lella M, Indira K.. A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia. J Adv Pharm Technol Res. 201;4(3):166-70.

Adsule SM, Baig MS, Gade PR, Khandelwal PN. Comparative evaluation of safety and efficacy of rosuvastatin, simvastatinand atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia.In J Diab Dev Ctries. 2009;29(2):74-9.

Bener A, Dogan M, Barakat L, Abdulla OAA Al-Hamaq. Comparison of efficacy, safety, and cost effectiveness of various statins in dyslipidemic diabetic patients. IJP. 2014;46(1):88-93.

Barakat L, Jayyousi M, Bener A, Zuby B, Zirie M. . Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients. ISRN Pharmacol. 2013;2013:1-7.

Stalenhoef AFH, Christie M. Ballantyne, Cinzia Sarti3, Jan Murin, Serena Tonstad,Helen Rose, and Wim Wilpshaar. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. 2005;26(24):2664-72.

Arshad AR. Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-Label Randomized Trial. Journal of Lipids. 2014;2014:1-5.

Khan MA, Murti K, Grover V. Atorvastatin vs Rosuvastatin; fenofibrate as an add on: an exploratory study. Int J of Pharmacy and pharmaceutical. 2014;6(8)493-8.

Eliasson B, Svensson A-M, Miftaraj M, Miao Jonasson J.Clinical Use and Effectiveness of Lipid Lowering Therapies in Diabetes Mellitus—An Observational Study from the Swedish National Diabetes Register. Plos one. 2011;6(4):18744.

Clearfield MB, Amerena J, Jean-Pierre B. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Eur Heart J. 2005;26(24):2664-72.

Karalis DG, Victor B, Ahedor L, Liu L. Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. Cholesterol. 2012;2012:1-7.